Pfizer (PFE) Announces FDA Approves Convenia for Dogs and Cats
More News related to PFE
- Court in Denmark Upholds Two Lipitor Patents, Prevents Launch of Ranbaxy Generic Product before November 2011
- Bristol-Myers (BMY) and Pfizer (PFE) Provide Update on Apixaban Clinical Development Program - Primary Endpoint Not Met
- Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
- Pfizer (PFE) Decides Not to Launch Phase III Study for Glaucoma Treatment in Asia - Reuters
- Barr Pharmaceuticals (BRL) Receives Approval for Generic Aredia
More News related to FDA
- Mylan (MYL) Subsidiary, Alphapharm, Wins Patent Challenge on First-to-fFile Opportunity Razadyne(R) Tablets
- Amylin (AMLN) Gets A Friend After Yesterday's 25% Sell-Off
- Barr Labs (BRL) Receives Final FDA Approval for Generic Version of Razadyne(R) Tablets
- Pro-Pharmaceuticals (PRW) Receives FDA IND Application for Use of DAVANAT(R)
- Valeant Pharmaceuticals (VRX) and GlaxoSmithKline Enter Collaboration for Retigabine
Pfizer (NYSE: PFE) Animal Health has announced the FDA has approved Convenia, the first and only antibiotic for dogs and cats available in a single veterinarian-administered injectable dose.
Convenia provides up to 14 days of antibiotic treatment in a single dose for the most common skin infections in dogs and cats – the No. 1 reason pets are prescribed antibiotics.
Related Categories
FDAStocks Mentioned
-0.16Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
